A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Conditions
Chronic Hepatitis B Virus (HBV) Infection
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Investigative Site 86001, Beijing, Beijing Municipality, China
Investigative Site 86003, Beijing, Beijing Municipality, China
Investigative Site 86004, Beijing, Beijing Municipality, China
Investigative Site 86005, Beijing, Beijing Municipality, China
Investigative Site 86016, Beijing, Beijing Municipality, China
Investigative Site 86002, Guangzhou, Guangdong, China
Investigative Site 86013, Guangzhou, Guangdong, China
Investigative Site 86015, Shenzhen, Guangdong, China
Investigative Site 86006, Shanghai, Shanghai Municipality, China
Investigative Site 86007, Shanghai, Shanghai Municipality, China
Investigative Site 86010, Chengdu, Sichuan, China
Investigative Site 86011, Chengdu, Sichuan, China
Investigative Site 86012, Chengdu, Sichuan, China
Investigative Site 86009, Hangzhou, Zhejiang, China
Study leads
Xiaofei Chen
Study Director
Brii Biosciences Limited